Ignite Creation Date:
2025-12-24 @ 11:54 AM
Ignite Modification Date:
2026-01-06 @ 2:14 PM
Study NCT ID:
NCT03357861
Status:
COMPLETED
Last Update Posted:
2021-10-26
First Post:
2017-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Sponsor:
University Hospital, Grenoble
Organization:
Study Overview
Official Title:
Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMMUNO-REA
Brief Summary:
This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.
Detailed Description:
The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is specific with adverse effects related to immunity. Some side effects (myocarditis, colitis, interstitial lung disease, etc.) can be severe and patient could be hospitalized in intensive care unit.
The question of immunotherapy's imputability in the acute disease is becoming more frequent.
The question of immunotherapy's imputability in the acute disease is becoming more frequent.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: